Higher coated-platelet levels are associated with chronic hypertension in patients with transient ischemic attack

Calin I Prodan1, Andrea S Vincent, George L Dale

  • 1Neurology Service, Department of Neurology, Veterans Administration Medical Center, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104, USA. calin-prodan@ouhsc.edu

Platelets
|June 23, 2012
PubMed

Insights

Coated-platelet levels, elevated in TIA patients, correlate with hypertension and longer symptom duration. This suggests a link between hypertension and increased platelet thrombotic potential in TIA.

Area of Science:

  • Hematology
  • Neurology
  • Cardiovascular Medicine

Background:

  • Coated-platelets are procoagulant platelets linked to transient ischemic attack (TIA) risk.
  • Previous studies show elevated coated-platelet levels in TIA patients correlating with ABCD2 scores.

Purpose of the Study:

  • To investigate the impact of individual ABCD2 score components on coated-platelet levels in TIA patients.
  • To explore the relationship between hypertension, symptom duration, and platelet procoagulant activity.

Main Methods:

  • Coated-platelet levels were measured in 124 TIA patients.
  • A nine-way ANOVA analyzed the influence of ABCD2 score elements, including blood pressure (BP) and hypertension (HTN), on coated-platelet levels.

Main Results:

  • Elevated BP (≥140/90) was initially associated with higher coated-platelet levels.
  • Hypertension (HTN) showed a significant main effect, with higher levels in HTN patients (46.3% vs. 33.6%, p<0.0001).
  • Longer symptom duration (≥60 minutes) also correlated with increased coated-platelet levels (42.5% vs. 37.4%, p=0.031).

Conclusions:

  • Hypertension is a significant factor associated with elevated coated-platelet levels in TIA patients.
  • Findings suggest a link between chronic hypertension and heightened platelet thrombotic potential.
  • Symptom duration may also influence platelet activation in TIA.

Related Concept Videos

Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...